A nine-amino-acid peptide first isolated during studies of sleep. Its function in people is not well understood.
Key takeaway
Delta sleep–inducing peptide was named for early animal experiments on sleep. Later research has not established a clear role or receptor.
At a glance
| FDA status | Not FDA-approved |
|---|---|
| 503A compounding | No 503A pathway: nomination withdrawn after FDA safety review |
| Body areas | Brain, mood & sleep |
| Through ScriptMates | Information only |
| Open questions | None noted |
What is DSIP (emideltide)?
Delta sleep–inducing peptide was named for early animal experiments on sleep. Later research has not established a clear role or receptor.
FDA says it has not identified safety information for the proposed routes.
Dosage forms
No FDA-approved dosage form. A standardized dosage form for human use was not confirmed from the sources below.
Is DSIP (emideltide) FDA-approved?
Not FDA-approved. Emideltide (DSIP) was nominated for the 503A bulks list and placed in Category 2 over safety concerns; the nomination was later withdrawn. FDA notes it has no, or only limited, safety information for the proposed uses.
Can it be prescribed through ScriptMates?
No 503A pathway: nomination withdrawn after FDA safety review. A partner pharmacy lists it, but it has no lawful 503A pathway today (nomination withdrawn after FDA safety review).
Sources
- FDA: Bulk substances that may present significant safety risks (Category 2 and withdrawn nominations)
- FDA: Bulk drug substances nominated under 503A, Categories 1–3 (May 14, 2026)
Checked October 27, 2026. FDA updates these pages, so confirm before relying on them.